CN111166763A - Bactericidal bacteriostatic agent - Google Patents
Bactericidal bacteriostatic agent Download PDFInfo
- Publication number
- CN111166763A CN111166763A CN202010096879.XA CN202010096879A CN111166763A CN 111166763 A CN111166763 A CN 111166763A CN 202010096879 A CN202010096879 A CN 202010096879A CN 111166763 A CN111166763 A CN 111166763A
- Authority
- CN
- China
- Prior art keywords
- bactericidal
- acid
- bacteriostatic agent
- nano
- zinc oxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000844 anti-bacterial effect Effects 0.000 title claims description 33
- 239000000022 bacteriostatic agent Substances 0.000 title claims description 21
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims abstract description 32
- 239000002253 acid Substances 0.000 claims abstract description 21
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 21
- 239000011787 zinc oxide Substances 0.000 claims abstract description 17
- 229920006317 cationic polymer Polymers 0.000 claims abstract description 16
- -1 nano silver ions Chemical class 0.000 claims abstract description 15
- 229920001661 Chitosan Polymers 0.000 claims abstract description 11
- 239000002904 solvent Substances 0.000 claims abstract description 11
- 150000004283 biguanides Chemical class 0.000 claims abstract description 10
- 125000003118 aryl group Chemical group 0.000 claims description 16
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 14
- 239000002861 polymer material Substances 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims description 7
- 125000004970 halomethyl group Chemical group 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000008213 purified water Substances 0.000 claims description 6
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 4
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims description 4
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 4
- 239000000174 gluconic acid Substances 0.000 claims description 4
- 235000012208 gluconic acid Nutrition 0.000 claims description 4
- 239000001630 malic acid Substances 0.000 claims description 4
- 235000011090 malic acid Nutrition 0.000 claims description 4
- 229920002492 poly(sulfone) Polymers 0.000 claims description 4
- 229920000728 polyester Polymers 0.000 claims description 4
- 239000004642 Polyimide Substances 0.000 claims description 3
- 239000004793 Polystyrene Substances 0.000 claims description 3
- 150000001408 amides Chemical class 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 229920006260 polyaryletherketone Polymers 0.000 claims description 3
- 229920001721 polyimide Polymers 0.000 claims description 3
- 229920002223 polystyrene Polymers 0.000 claims description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 239000003899 bactericide agent Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 14
- 230000001954 sterilising effect Effects 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 229910052709 silver Inorganic materials 0.000 description 10
- 239000004332 silver Substances 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 230000003385 bacteriostatic effect Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000000249 desinfective effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- RONFGUROBZGJKP-UHFFFAOYSA-N iminoctadine Chemical compound NC(N)=NCCCCCCCCNCCCCCCCCN=C(N)N RONFGUROBZGJKP-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010012504 Dermatophytosis Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241001460074 Microsporum distortum Species 0.000 description 1
- 206010058667 Oral toxicity Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 231100000418 oral toxicity Toxicity 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
The invention discloses a sterilization bacteriostat, which is characterized by comprising, by mass, 0.1-0.3 wt% of chitosan, 0.2-1 wt% of cationic polymer, 0.2-2 wt% of fruit acid, 0.5-4 wt% of nano zinc oxide, 0.1-1 wt% of nano silver ions, 0.8-4 wt% of biguanide salt and the balance of solvent. The sterilization bacteriostat has the advantages of rich raw material sources, low manufacturing cost, sterilization and bacteriostasis efficacies and small side effect.
Description
Technical Field
The invention belongs to the technical field of sterilization and bacteriostasis, and relates to a sterilization and bacteriostasis agent.
Background
Wounds can be defined as skin injuries caused by mechanical, electrical, thermal, chemical and other factors, and common injuries of human skin mainly include burns, scalds, acute or chronic ulcers, surgical wounds and the like. After extensive damage to the skin, bacterial infection, loss of body fluids and various complications occur, which can lead to increased metabolism, decreased body temperature, excessive loss of water and proteins, and disturbances of the endocrine and immune systems, which are associated with loss of the skin barrier function, and can even be life threatening. At present, most of the bacteriostatic and bactericidal preparations on the market are chemical components serving as main components, the bacteriostatic and bactericidal effect is not ideal, and in addition, after long-time use, the bacterial fungi are easy to generate tolerance, and the environment can be polluted by increasing the use dosage. Therefore, it is desirable to provide a bactericidal bacteriostatic agent.
Disclosure of Invention
In order to overcome the defects in the prior art, a bactericidal bacteriostatic agent is provided.
The invention is realized by the following scheme:
a sterilization bacteriostat is characterized in that: the bactericidal bacteriostatic agent comprises, by mass, 0.1-0.3 wt% of chitosan, 0.2-1 wt% of cationic polymer, 0.2-2 wt% of fruit acid, 0.5-4 wt% of nano zinc oxide, 0.1-1 wt% of nano silver ions, 0.8-4 wt% of biguanide salt and the balance of solvent.
The solvent is purified water.
The cationic polymer is an aromatic polymer material with halomethyl grafted on the surface, and the aromatic polymer material comprises one or more of polysulfone, polyimide, polyaromatic amide, polyaryletherketone, polystyrene and aromatic polyester.
The fruit acid is one or more of gluconic acid, malic acid, citrus acid and lactic acid; the content of effective substances in the fruit acid is more than 99%.
The grain diameter of the nano zinc oxide is less than 5 nanometers.
The nano silver ions are trivalent nano silver.
The method has the beneficial effects that:
the sterilization bacteriostat has the advantages of rich raw material sources, low manufacturing cost, sterilization and bacteriostasis efficacies and small side effect.
Detailed Description
The invention is further illustrated by the following specific examples:
the application discloses a bactericidal bacteriostatic agent which is characterized by comprising, by mass, 0.1-0.3 wt% of chitosan, 0.2-1 wt% of cationic polymer, 0.2-2 wt% of fruit acid, 0.5-4 wt% of nano zinc oxide, 0.1-1 wt% of nano silver ions, 0.8-4 wt% of biguanide salt and the balance of solvent.
Wherein the solvent is purified water. The cationic polymer is an aromatic polymer material with halomethyl grafted on the surface, and the aromatic polymer material comprises one or more of polysulfone, polyimide, polyaromatic amide, polyaryletherketone, polystyrene and aromatic polyester.
The fruit acid is one or more of gluconic acid, malic acid, citrus acid and lactic acid; the content of effective substances in the fruit acid is more than 99%. The grain diameter of the nano zinc oxide is less than 5 nanometers. The nano silver ions are trivalent nano silver.
The chitosan can increase the adhesive force and the air adsorption capacity, increase the capacity of the sterilization bacteriostat for adsorbing microorganisms and spores, and can be bonded to kill the microorganisms. The cationic polymer has good durability, can quickly kill microorganisms and spores, and has excellent antibacterial and bacteriostatic effects. The biguanide salt has the effects of sterilization and bacteriostasis, and the main antibacterial effect of the biguanide salt is to inhibit the biosynthesis of lipid in thalli.
The fruit acid is natural organic acid, so that the fruit acid has no toxic or side effect on the whole body, is a nutrient substance beneficial to the skin and has good nourishing effect on the skin. The application of the fruit acid can improve the dispersibility of each component and is used for modifying the nano zinc oxide, and the nano zinc oxide can continuously sterilize and inhibit bacteria.
When two trivalent silver ions in the trivalent nano silver molecular structure meet microorganisms, the trivalent silver ions can be strongly combined with sulfydryl on proteins, so that the proteins on the microorganisms are inactivated. The sterilization of the substance is different from the traditional disinfectant, namely the 'group' sterilization, but belongs to the 'attack' sterilization mode. Meanwhile, trivalent silver continuously obtains electrons and is converted into divalent silver, and monovalent silver can keep bactericidal activity until being converted into silver. This makes the efficacy of the present application far superior to common disinfecting solutions.
The killing rate of the trivalent nano silver molecules on escherichia coli, staphylococcus aureus and candida albicans can reach more than 99.999 percent within minutes. Oral toxicity test of animals in animal experiment center of Compound Dan university shows that LD50 is greater than 5000mg/kg, and shows that the nanometer trivalent ion silver solution is a nontoxic product. Because the nanometer trivalent ion silver has colorless, tasteless, nontoxic and high-efficiency broad-spectrum bactericidal capability, the nanometer trivalent ion silver can be used in the daily chemical fields of disinfection, textile, water treatment and the like, and can also be applied in the treatment fields of dermatophytosis and various skin diseases caused by microorganisms.
Example 1
The bactericidal and bacteriostatic agent is characterized by comprising, by mass, 0.1 wt% of chitosan, 0.2 wt% of cationic polymer, 0.2 wt% of tartaric acid, 0.5 wt% of nano zinc oxide, 0.1 wt% of nano silver ions, 0.8 wt% of biguanide salt and the balance of solvent.
Wherein the solvent is purified water. The cationic polymer is an aromatic polymer material with halomethyl grafted on the surface, and the aromatic polymer material is polysulfone. The fruit acid is gluconic acid; the content of effective substances in the fruit acid is more than 99%. The grain diameter of the nano zinc oxide is less than 5 nanometers. The nano silver ions are trivalent nano silver.
Example 2
In this embodiment, the same points as those in embodiment 1 are not repeated, but the difference is that in this embodiment, the bactericidal bacteriostatic agent includes, by mass, 0.2 wt% of chitosan, 0.6 wt% of cationic polymer, 1 wt% of fruit acid, 2 wt% of nano zinc oxide, 0.5 wt% of nano silver ions, 2 wt% of guazatine, and the balance purified water. The cationic polymer is an aromatic polymer material with halomethyl grafted on the surface, the aromatic polymer material is polyaramide, and the fruit acid is citrus acid.
Example 3
In this embodiment, the same points as those in embodiment 1 are not repeated, except that, in this embodiment, the bactericidal bacteriostatic agent includes, by mass, 0.3 wt% of chitosan, 1 wt% of cationic polymer, 2 wt% of fruit acid, 4 wt% of nano zinc oxide, 1 wt% of nano silver ions, 4 wt% of guazatine, and the balance purified water. The cationic polymer is an aromatic polymer material with halomethyl grafted on the surface, the aromatic polymer material is aromatic polyester, and the fruit acid is malic acid.
Comparative example 1
In this comparative example, the same points as those in example 1 are not repeated, except that, in this example, the bactericidal bacteriostatic agent includes, by mass, 0.2 wt% of chitosan, 0.6 wt% of cationic polymer, 1 wt% of fruit acid, 0 wt% of nano-zinc oxide, 0.5 wt% of nano-silver ions, 2 wt% of biguanide salt, and the balance solvent.
Comparative example 2
In this comparative example, the same points as those in example 1 are not repeated, except that, in this example, the bactericidal bacteriostatic agent includes, by mass, 0.2 wt% of chitosan, 0.6 wt% of cationic polymer, 1 wt% of fruit acid, 2 wt% of nano-zinc oxide, 0 wt% of nano-silver ions, 2 wt% of biguanide salt, and the balance solvent.
The bacteriostat rates of the bactericidal bacteriostats of the examples and the comparative examples are detected, the detection process is carried out according to the method of GB/T2378-2012, and the detection results are shown in tables 1 to 3 below. As can be seen from tables 1 to 3, the bacteriostatic agents of the present application have excellent bactericidal effects, the bactericidal rates of the bacteriostatic agents of examples 1 to 3 all exceed 90%, while the bactericidal rates of the bacteriostatic agents of comparative examples 1 to 2 do not exceed 90%. This application chitosan increases adhesive force and air adsorption capacity, fruit acid can promote the dispersibility of each component, and be used for the modification of nanometer zinc oxide, and nanometer zinc oxide can continuously disinfect antibacterial, trivalent nanometer silver and biguanide salt continue to disinfect antibacterial, synergistic effect through several kinds of components, the bacteriostat grass of disinfecting of this application has stronger suppression and exterminates the effect to staphylococcus aureus, escherichia coli, copper pseudomonad etc. compares with current product, has better bactericidal effect.
TABLE 1 bacteriostasis rate of the present bactericidal bacteriostat (Staphylococcus aureus)
TABLE 2 inhibition ratio of the antibacterial bacteriostatic agent (Escherichia coli) of the present application
TABLE 3 bacteriostasis rate of the bactericidal bacteriostat of the present application (Pseudomonas aeruginosa)
Although the invention has been described and illustrated in some detail, it should be understood that various modifications may be made to the described embodiments or equivalents may be substituted, as will be apparent to those skilled in the art, without departing from the spirit of the invention.
Claims (6)
1. The bactericidal and bacteriostatic agent is characterized by comprising, by mass, 0.1-0.3 wt% of chitosan, 0.2-1 wt% of cationic polymer, 0.2-2 wt% of tartaric acid, 0.5-4 wt% of nano zinc oxide, 0.1-1 wt% of nano silver ions, 0.8-4 wt% of biguanide salt and the balance of solvent.
2. The bactericidal bacteriostatic agent of claim 1, which is characterized in that: the solvent is purified water.
3. The bactericidal bacteriostatic agent of claim 1, which is characterized in that: the cationic polymer is an aromatic polymer material with halomethyl grafted on the surface, and the aromatic polymer material comprises one or more of polysulfone, polyimide, polyaromatic amide, polyaryletherketone, polystyrene and aromatic polyester.
4. The bactericidal bacteriostatic agent of claim 1, which is characterized in that: the fruit acid is one or more of gluconic acid, malic acid, citrus acid and lactic acid; the content of effective substances in the fruit acid is more than 99%.
5. The bactericidal bacteriostatic agent of claim 1, which is characterized in that: the grain diameter of the nano zinc oxide is less than 5 nanometers.
6. The bactericidal bacteriostatic agent of claim 1, which is characterized in that: the nano silver ions are trivalent nano silver.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010096879.XA CN111166763A (en) | 2020-02-17 | 2020-02-17 | Bactericidal bacteriostatic agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010096879.XA CN111166763A (en) | 2020-02-17 | 2020-02-17 | Bactericidal bacteriostatic agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111166763A true CN111166763A (en) | 2020-05-19 |
Family
ID=70624221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010096879.XA Pending CN111166763A (en) | 2020-02-17 | 2020-02-17 | Bactericidal bacteriostatic agent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111166763A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114569473A (en) * | 2022-02-10 | 2022-06-03 | 士露洁家化(武汉)有限公司 | Environment-friendly washing-free antibacterial gel and preparation method thereof |
| CN116510459A (en) * | 2022-01-22 | 2023-08-01 | 华懋科技股份有限公司 | Antibacterial tubular adsorption material module |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1878536A (en) * | 2003-09-09 | 2006-12-13 | 3M创新有限公司 | Antimicrobial compositions and methods |
| CN104815096A (en) * | 2015-05-04 | 2015-08-05 | 中国人民解放军疾病预防控制所 | Nano composite skin disinfection emulsion and preparation method of same |
| CN105407718A (en) * | 2013-06-04 | 2016-03-16 | 维奥姆生物科学有限公司 | Coated particles and compositions comprising same |
| CN106176960A (en) * | 2016-07-12 | 2016-12-07 | 泉州亚林新材料科技有限公司 | A kind of natural antibacterial spray |
| CN108065750A (en) * | 2016-11-14 | 2018-05-25 | 佛山市顺德区美的电热电器制造有限公司 | Production method and the non-stick pan tool and its manufacturing method of a kind of tick marks |
| CN108203517A (en) * | 2017-06-26 | 2018-06-26 | 哈尔滨工业大学（威海） | A kind of preparation method of aromatic polymer material surface grafted cation fungistatic coating |
| CN108605986A (en) * | 2018-05-25 | 2018-10-02 | 苏州佑君环境科技有限公司 | A kind of oil field composite bactericide and preparation method thereof |
-
2020
- 2020-02-17 CN CN202010096879.XA patent/CN111166763A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1878536A (en) * | 2003-09-09 | 2006-12-13 | 3M创新有限公司 | Antimicrobial compositions and methods |
| CN105407718A (en) * | 2013-06-04 | 2016-03-16 | 维奥姆生物科学有限公司 | Coated particles and compositions comprising same |
| CN104815096A (en) * | 2015-05-04 | 2015-08-05 | 中国人民解放军疾病预防控制所 | Nano composite skin disinfection emulsion and preparation method of same |
| CN106176960A (en) * | 2016-07-12 | 2016-12-07 | 泉州亚林新材料科技有限公司 | A kind of natural antibacterial spray |
| CN108065750A (en) * | 2016-11-14 | 2018-05-25 | 佛山市顺德区美的电热电器制造有限公司 | Production method and the non-stick pan tool and its manufacturing method of a kind of tick marks |
| CN108203517A (en) * | 2017-06-26 | 2018-06-26 | 哈尔滨工业大学（威海） | A kind of preparation method of aromatic polymer material surface grafted cation fungistatic coating |
| CN108605986A (en) * | 2018-05-25 | 2018-10-02 | 苏州佑君环境科技有限公司 | A kind of oil field composite bactericide and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 曾化雨: "纳米技术在高分子材料改性中的应用探析", 《科学管理》 * |
| 汪多仁主编: "《绿色化工助剂》", 31 January 2006, 科学技术文献出版社 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116510459A (en) * | 2022-01-22 | 2023-08-01 | 华懋科技股份有限公司 | Antibacterial tubular adsorption material module |
| CN114569473A (en) * | 2022-02-10 | 2022-06-03 | 士露洁家化(武汉)有限公司 | Environment-friendly washing-free antibacterial gel and preparation method thereof |
| CN114569473B (en) * | 2022-02-10 | 2024-02-02 | 士露洁家化(武汉)有限公司 | Environment-friendly wash-free antibacterial gel and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Percival et al. | Antiseptics for treating infected wounds: efficacy on biofilms and effect of pH | |
| Mahira et al. | Antimicrobial materials—An overview | |
| EP1998615B1 (en) | Antimicrobial composition | |
| AU2005282377B2 (en) | Cationic antiseptic compositions and methods of use | |
| US20030118705A1 (en) | Composition for disinfection of plants, animals, humans, byproducts of plants and animals and articles infected with pathogens and method of producing and application of same | |
| WO2012013577A1 (en) | Composition for coating medical devices containing lae and a polycationic amphoteric polymer | |
| Sousa et al. | Mini-review: antimicrobial central venous catheters–recent advances and strategies | |
| EP2525662A2 (en) | Treatment of biofilms | |
| CN104546717A (en) | Highly-antibacterial chitosan film-forming agent and preparation method thereof | |
| Moratti et al. | Antibacterial properties of chitosan | |
| CN102499243A (en) | Biological disinfectant | |
| CN111166763A (en) | Bactericidal bacteriostatic agent | |
| EP1635850B1 (en) | Antimicrobial silver comprising silver | |
| CN104559648A (en) | Bactericidal coating | |
| CN104686511A (en) | Novel efficient sterilizing and bacteriostatic agent | |
| US20230227682A1 (en) | Surface-functionalized material and modified material, and preparation methods therefor and use thereof | |
| Anandakumar | Nano-antibacterial materials as an alternative antimicrobial strategy | |
| CN107258814A (en) | A kind of composite disinfectant of Quick disinfection sterilization and its preparation method and application | |
| KR20210038465A (en) | Composite for antibacterial and deodorant agent using ionized minerals and persimmon leaf extract and other natural materials | |
| CN113080207A (en) | Process for preparing disinfectant | |
| CN112021327A (en) | Photocatalyst composite long-acting disinfectant and preparation method thereof | |
| CN114569473B (en) | Environment-friendly wash-free antibacterial gel and preparation method thereof | |
| CN104686578A (en) | Composite antibacterial powder | |
| CN1063610C (en) | Broad-spectrum fungicide | |
| CN111218180A (en) | Breathable bacteriostatic coating composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200519 |